AMGN · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

AMGEN INC · 2026-11-04 · Importance 49 · Surprise 32

Worldwide product sales for the three months ended September 30, 2026 rose 8% to $9.883 billion from $9.137 billion, and nine-month sales rose 7% to $27.638 billion from $25.781 billion. Repatha sales increased on volume growth, while EVENITY, BLINCYTO, TEZSPIRE, UPLIZNA and IMDELLTRA/IMDYLLTRA also grew primarily through volume; nine-month Nplate sales increased 15%, including 13% growth excluding U.S. government orders. Competition and pricing pressure weighed on products including Prolia, down 45% for the quarter and 37% for nine months, and XGEVA, down 47% and 36%, respectively, as biosimilars launched in the United States and rest of world (ROW). Nine-month sales also declined 14% for Otezla and 11% for ENBREL, with Otezla affected by lower volume and pricing and ENBREL by Medicare Part D price setting and increased 340B Program mix.

Key facts

• Amgen’s other revenues increased 15% and 27% for the three and nine months ended September 30, 2026, respectively, driven by higher royalty income and corporate partner revenue. source
• Amgen’s total product sales increased 8% for the three months ended September 30, 2026, driven by volume growth. source
• Amgen’s total product sales increased 7% for the nine months ended September 30, 2026, driven by 10% volume growth partially offset by lower net selling price. source
• For the three months ended September 30, 2026, Amgen’s U.S. volume grew 8% and ROW volume grew 16%, driven by Repatha, UPLIZNA, EVENITY, IMDELLTRA/IMDYLLTRA, TEZSPIRE and PAVBLU. source
• For the nine months ended September 30, 2026, Amgen’s U.S. volume grew 8% and ROW volume grew 12%, driven by Repatha, UPLIZNA, EVENITY, IMDELLTRA/IMDYLLTRA, PAVBLU and TEZSPIRE. source
• Global TEPEZZA sales increased in the nine months ended September 30, 2026, primarily driven by higher net selling price of 6% and higher inventory. source
• Global Aranesp sales decreased in the nine months ended September 30, 2026, driven by lower net selling price of 3% and lower volume. source
• Global EVENITY sales increased in the three and nine months ended September 30, 2026, driven by volume growth. source